Protagonist

PTGX NASDAQ
11.92
+0.10
+0.85%
Opening 14:16 06/25 EDT
Open
11.81
Prev Close
11.82
High
12.12
Low
11.64
Volume
49.04K
Avg Vol (3M)
205.44K
52 Week High
14.36
52 Week Low
5.49
% Turnover
0.21%
Market Cap
278.88M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Protagonist PTGX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
MORE >

Recently

Name
Price
%Change